Abstract ND10: Discovery of MRT-2359, an orally bioavailable GSPT1 molecular glue degrader, for MYC-driven cancers

肺癌 医学 癌症研究 癌症 内科学 肿瘤科
作者
Owen B. Wallace,Gérald Gavory,Mahmoud Ghandi,Anne-Cecile d’Alessandro,Débora Bonenfant,Maciej Cabanski,Lisa Cantagallo,Agustin Chicas,Qian Chen,Anna Diesslin,Christopher King,Vittoria Massafra,Rajiv Narayan,Arnaud Osmont,Dave Peck,Carolina Perdomo Ortiz,Martin Schillo,Ambika Singh,Ralph Tiedt,Simone Tortoioli,Silvia Buonamici,Markus Warmuth,Filip Jankú,Bernhard Fasching
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:83 (7_Supplement): ND10-ND10
标识
DOI:10.1158/1538-7445.am2023-nd10
摘要

Abstract MYC transcription factors have been demonstrated to be drivers of many cancers, yet have remained recalcitrant to new drug development. We hypothesized that MYC-driven cancer cell lines are addicted to protein translation, and therefore are vulnerable to the loss of the translation termination factor, GSPT1. We have discovered MRT-2359, a selective GSPT1 molecular glue degrader, that demonstrates potent and preferential antiproliferative activity in MYC-driven cell lines, such as high N- and L-MYC mRNA expressing non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) lines. MRT-2359 has been optimized for differential toxicity between MYC- and non-MYC-driven cancer cell lines, kinetics and depth of degradation, oral bioavailability, and in vivo efficacy. The anti-tumor activity of MRT-2359 was assessed in more than 80 lung patient-derived xenografts (PDXs) that confirmed the preferential anti-tumor activity in N- and L-MYC high NSCLC and SCLC PDXs when dosed orally daily or intermittently. Similar levels of activity were also observed in neuroendocrine lung cancer PDXs and lymphoma models. Oral MRT-2359 is currently in a Phase 1/2 clinical trial in selected cancer patients with MYC-driven NSCLC, SCLC, high grade neuroendocrine cancers and diffuse large B-cell lymphoma (NCT05546268). Citation Format: Owen B. Wallace, Gerald Gavory, Mahmoud Ghandi, Anne-Cecile d’Alessandro, Debora Bonenfant, Maciej Cabanski, Lisa Cantagallo, Agustin Chicas, Qian Chen, Anna Diesslin, Christopher King, Vittoria Massafra, Rajiv Narayan, Arnaud Osmont, Dave Peck, Carolina Perdomo Ortiz, Martin Schillo, Ambika Singh, Ralph Tiedt, Simone Tortoioli, Silvia Buonamici, Markus Warmuth, Filip Janku, Bernhard Fasching. Discovery of MRT-2359, an orally bioavailable GSPT1 molecular glue degrader, for MYC-driven cancers [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr ND10.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
野性的沉鱼完成签到,获得积分10
刚刚
3秒前
阿超完成签到,获得积分10
3秒前
kkkkkkk_完成签到,获得积分10
4秒前
杨幂完成签到,获得积分10
5秒前
啊啊啊lei发布了新的文献求助10
6秒前
华仔应助gtgyh采纳,获得10
8秒前
orixero应助cannon8采纳,获得10
8秒前
8秒前
友好的蛋挞完成签到 ,获得积分10
8秒前
wxr发布了新的文献求助10
9秒前
wwqc完成签到,获得积分0
9秒前
11秒前
dxs完成签到 ,获得积分10
11秒前
wanci应助活泼的电脑采纳,获得10
11秒前
谦如完成签到,获得积分10
11秒前
酷波er应助DQ采纳,获得10
12秒前
13秒前
小鹿发布了新的文献求助10
15秒前
xxx关注了科研通微信公众号
16秒前
jin完成签到,获得积分20
17秒前
19秒前
20秒前
不下雨完成签到,获得积分10
20秒前
853225598完成签到,获得积分10
20秒前
26秒前
26秒前
Orange应助结实的德地采纳,获得10
26秒前
27秒前
雅典娜完成签到,获得积分10
27秒前
123完成签到,获得积分10
28秒前
29秒前
藏识发布了新的文献求助200
30秒前
qgd完成签到 ,获得积分10
31秒前
戴饱饱发布了新的文献求助10
31秒前
Amazing发布了新的文献求助10
32秒前
乐乐应助科研通管家采纳,获得10
35秒前
大个应助jbear采纳,获得10
35秒前
35秒前
烟花应助科研通管家采纳,获得10
35秒前
高分求助中
The ACS Guide to Scholarly Communication 2500
Sustainability in Tides Chemistry 2000
Pharmacogenomics: Applications to Patient Care, Third Edition 1000
Studien zur Ideengeschichte der Gesetzgebung 1000
TM 5-855-1(Fundamentals of protective design for conventional weapons) 1000
Threaded Harmony: A Sustainable Approach to Fashion 810
Genera Insectorum: Mantodea, Fam. Mantidæ, Subfam. Hymenopodinæ (Classic Reprint) 800
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3085527
求助须知:如何正确求助?哪些是违规求助? 2738431
关于积分的说明 7549700
捐赠科研通 2388188
什么是DOI,文献DOI怎么找? 1266339
科研通“疑难数据库(出版商)”最低求助积分说明 613430
版权声明 598591